Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback